Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms OrPHeUS
- Sponsors Actelion Pharmaceuticals
- 25 Sep 2018 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Planned End Date changed from 15 Jan 2018 to 17 Oct 2018.
- 22 Jan 2018 Planned primary completion date changed from 15 Jan 2018 to 17 Oct 2018.